1. Home
  2. BMEA vs LGO Comparison

BMEA vs LGO Comparison

Compare BMEA & LGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Biomea Fusion Inc.

BMEA

Biomea Fusion Inc.

HOLD

Current Price

$1.52

Market Cap

107.7M

Sector

Health Care

ML Signal

HOLD

LGO

Largo Inc.

HOLD

Current Price

$1.24

Market Cap

104.6M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
BMEA
LGO
Founded
2017
1988
Country
United States
Canada
Employees
41
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
107.7M
104.6M
IPO Year
2021
2007

Fundamental Metrics

Financial Performance
Metric
BMEA
LGO
Price
$1.52
$1.24
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
7
2
Target Price
$8.86
$3.40
AVG Volume (30 Days)
1.3M
1.4M
Earning Date
05-04-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
69.19
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$53.91
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.87
$0.85
52 Week High
$3.07
$2.70

Technical Indicators

Market Signals
Indicator
BMEA
LGO
Relative Strength Index (RSI) 62.69 46.51
Support Level $1.22 $1.23
Resistance Level $1.66 $1.25
Average True Range (ATR) 0.13 0.08
MACD 0.03 0.00
Stochastic Oscillator 86.54 57.38

Price Performance

Historical Comparison
BMEA
LGO

About BMEA Biomea Fusion Inc.

Biomea Fusion Inc is a a clinical stage diabetes and obesity medicines company focused on the discovery and development of oral, small molecule drugs to treat and improve the lives of patients with diabetes, obesity, and other metabolic diseases. It operate as an organization centered on two of its core drug candidate development programs: (i) icovamenib, its clinical program's drug candidate, currently being developed as an orally bioavailable, and selective, covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity, and (ii) BMF-650, its investigational, next-generation oral glucagon-like peptide-1 GLP-1 receptor agonist in development for the treatment of obesity.

About LGO Largo Inc.

Largo Inc is committed to the production and supply of high-quality vanadium products. The company is also focused on the advancement of renewable energy storage solutions through Largo Clean Energy and its vanadium redox flow battery technology. The Company is engaged in the mining, exploration, and development of mineral properties, predominantly in Brazil, through which it produces and supplies vanadium products VPURE Flake, VPURE+ Flake, and VPURE+ Powder. The company has operating segments: sales & trading, mine properties, which generates key revenue, corporate, exploration and evaluation properties, Clean Energy, and Largo Physical Vanadium.

Share on Social Networks: